Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer
Metformin is a biguanide oral hypoglycaemic agent commonly used for the treatment of type 2 diabetes mellitus. In addition to its anti-diabetic effect, metformin has also been associated with a reduced risk of...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Danielle Crawley, Ashish Chandra, Massimo Loda, Cheryl Gillett, Paul Cathcart, Ben Challacombe, Gary Cook, Declan Cahill, Aida Santa Olalla, Fidelma Cahill, Gincy George, Sarah Rudman and Mieke Van Hemelrijck Source Type: research
More News: Cancer | Cancer & Oncology | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Metformin | Oral Cancer | Prostate Cancer | Study